[How evidence-based are print- and online mass media in Austria? A quantitative analysis].

B. Kerschner,J. Wipplinger,I. Klerings,G. Gartlehner

DOI: https://doi.org/10.1016/j.zefq.2015.05.014

Abstract:

What problem does this paper attempt to address?

Utility of triple tumor markers CA19-9, CA125 and CEA in predicting advanced stage of carcinoma gallbladder: a retrospective study

Navin Kumar,Deepak Rajput,Amit Gupta,Varun Popuri,Ashikesh Kundal,Jyoti Sharma,Nisanth Puliyath,Sruthi Shasheendran

DOI: https://doi.org/10.18203/2349-2902.isj20203049

2020-07-23

International Surgery Journal

Abstract:Background: A combination of serum tumor markers are used in the evaluation and prognosis of carcinoma gallbladder (GBC). Aim of the study was to find the significance of combined use of CA19-9, CA125 and CEA in advanced stage of GBC and to find the cut-off value of each of these tumor markers in metastatic GBC. Methods: This was a retrospective observational cohort study over 1 year, which was carried out in 42 cases of advanced GBC. The patients were grouped in to locally advanced and metastatic stage on the basis of CECT scan findings. CA19-9, CA125 and CEA were assayed in all patients. These tumor markers were analysed with these two groups of GBCs. Statistical analysis was performed using R statistical software v3.6.2.Results: Out of 42 cases CA19-9 was elevated in 18 (78%), CA125 in 16 (70%) and CEA in 9 (39%) patients with metastatic disease. The cut-off value of CA19-9, CA125 and CEA was determined by ROC curve were >109 U/ml, 55.4 U/ml and 2.56 μg/l respectively. CA19-9 had the highest sensitivity 78.3% followed by CA125 69.6% and CEA has the highest specificity 68.4% for the diagnosis of metastatic stage of the disease. Specificity of these tumor markers were highest when used in combination.Conclusions: Combined use of triple tumor markers increases its specificity in the diagnosis of advanced stage of GBC but their cut-off level is statistically not significant in predicting metastatic GBC.
[Analysis of Treatment Modalities and Prognosis of Patients with Gallbladder Cancer in China from 2010 to 2017].

T Ren,Y S Li,Y J Geng,M L Li,X S Wu,W,X A Wang,Y J Shu,R F Bao,P Dong,W Gong,J Gu,X F Wang,J H Lu,J S Mu,W H Pan,X Zhang,X L Zhang,Z W Fei,Z Y Zhang,Y Wang,H Cao,B Sun,Y F Cui,C F Zhu,B Li,L H Zheng,Y B Qian,J Liu,X Y Dang,C Liu,S Y Peng,Z W Quan,Y B Liu

DOI: https://doi.org/10.3760/cma.j.cn112139-20200403-00279

2020-01-01

Abstract:Objective: To evaluate the clinical characteristics and prognosis of gallbladder cancer (GBC) patients in China. Methods: This retrospective multicenter cohort study enrolled 3 528 consecutive GBC patients diagnosed between January 2010 to December 2017 in 15 hospitals from 10 provinces. There were 1 345 (38.12%) males and 2 183 (61.88%) females.The age of diagnosis was (63.7±10.8) years old (range: 26 to 99 years old) .There were 213 patients (6.04%) in stage 0 to Ⅰ, whereas 1 059 (30.02%) in stage Ⅱ to Ⅲ, 1 874 (53.12%) in stage Ⅳ, and 382 (10.83%) unavailable. Surgery was performed on 2 255 patients (63.92%) . Three hundred and thirty-six patients received chemotherapy or radiotherapy (9.52%; of which 172 were palliative); 1 101 (31.21%) received only supportive treatment.The patient source, treatment and surgery, pathology, concomitant gallstone, and prognosis were analyzed. Results: Among the 3 528 GBC patients, 959 (27.18%) were from East China, 603 (17.09%) from East-North China, 1 533 (43.45%) from Central China, and 433(12.27%) from West China. Among the 1 578 resectable tumor, 665 (42.14%) underwent radical surgery, 913 (57.86%) underwent surgery that failed to follow the guidelines.Eight hundred and ninety-one (56.46%) patients were diagnosed before surgery, 254 (16.10%) during surgery, and 381 (24.14%) after surgery (time point of diagnosis couldn't be determined in 52 patients) .Among the 1 578 patients with resectable tumor, 759 (48.10%) had concomitant gallstone.Among the 665 patients underwent radical surgery, 69 (10.4%) showed positive resection margin, 510 (76.7%) showed negative resection margin, and 86 (12.9%) unreported margin status.The 5-year overall survival rate (5yOS) for the 3 528-patient cohort was 23.0%.The 5yOS for patients with resectable tumor was 39.6%, for patients with stage ⅣB tumor without surgery was 5.4%, and for patients with stage ⅣB tumor underwent palliative surgery was 4.7%. Conclusions: More than half GBC patients in China are diagnosed in stage Ⅳ.Curative intent surgery is valuable in improving prognosis of resectable GBC.The treatment of GBC needs further standardization.Effective comprehensive treatment for GBC is in urgent need.
Nanopatterned PMMA-Yb:Er/Tm:Lu2O3 composites with visible upconversion emissions

Xiumei Han,J. Maiz,C. Mijangos,C. Zaldo

DOI: https://doi.org/10.1088/0957-4484/25/20/205302

IF: 3.5

2014-05-23

Nanotechnology

Abstract:Nanopillars, nanotubes and nanofibers of transparent polymethyl methacrylate (PMMA) polymer with Yb:Ln:Lu2O3 (Ln = Er or Tm) nanoparticles (NPs) (≈30–35 nm average size) have been prepared by infiltration of anodized aluminum oxide hexagonally nanopatterned templates. The outer diameter of these nanostructures is in the 330–400 nm range, with lengths up to 50 μm and a period distance of 430 nm. These nanostructures show visible upconversion (UC) emissions under excitation with 978 nm light. The steady state temperature of the polymer nanostructures is optically evidenced by the Er3+ UC emission and optically controlled around the PMMA glass transition temperature by the excitation light, introducing a new method for NP storage in a solid and potential optically induced particle release. Full color emission is shown in tridoped (Yb:Er:Tm) samples.
Serum Levels of Interleukin-6 and Tumor Necrosis Factor-Alpha in Diagnosis and Prognosis of Gallbladder Cancer: A Pilot Study

Poonam Sharma,Sarath Krishnan M P,Amit Gupta,Sweety Gupta,Rahul Saxena,Anissa Atif Mirza,Bela Goyal

DOI: https://doi.org/10.1055/s-0043-1772772

2023-08-25

Journal of Laboratory Physicians

Abstract:Objectives Interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) are proinflammatory cytokines that play a major role in tumorigenesis. These biomarkers are relatively unexplored in gallbladder cancer (GBC) for their diagnostic and prognostic utility. Material and Methods A total of 40 healthy controls and 40 GBC patients were recruited. Serum IL-6 and TNF-α levels were measured, and their diagnostic utility was analyzed using the receiver operating characteristics (ROC) curve. The relationship between clinicopathological variables and serum tumor markers (CEA, CA125, and CA19-9) in identifying GBC patients was also assessed. Results Serum IL-6 and TNF-α expression were significantly higher in the GBC group (for both IL-6 and TNF-α, p = 0.0001) than in healthy controls. ROC analysis revealed that the areas under the curve for serum IL-6 and TNF-α were 0.89 and 0.71, respectively. The sensitivity and specificity for serum IL-6 were 82.5 and 97.5%, respectively, at an optimal cutoff value of 10.34 pg/mL; for TNF-α, they were 40.0 and 100%, respectively, at a cutoff value of 0.24 pg/mL. There was also a significant difference in serum IL-6 levels between the resectable and nonresectable GBC groups. Serum IL-6 showed a positive correlation with CA125 ( r = 0.34, p < 0.05), while no correlation was observed between serum TNF-α and serum tumor markers (CEA, CA125, and CA19-9). Conclusion Serum IL-6 may serve as a diagnostic marker and a predictor of resectability, and it can be used in conjunction with other serum tumor markers in GBC. Ethical approval was given by the All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India, under reference number 422/IEC/M. Sc/2020. * Co-first authors. Article published online: 24 August 2023 © 2023. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
Raised carbohydrate antigen 19-9 levels detect recurrences and impacts overall and disease-free survival in radically resected gallbladder cancer: A simple surveillance marker?

Sushma Agrawal,Rajan Saxena

DOI: https://doi.org/10.4103/jcrt.jcrt_702_20

2021-01-01

Journal of Cancer Research and Therapeutics

Abstract:Background: There are no established markers which can be used for surveillance after curative resection in gallbladder carcinoma (GBC). Though carbohydrate antigen 19-9 (CA 19-9) has low specificity as a diagnostic marker, its role as a surveillance marker has not been explored. The aim of this study is to evaluate the predictive ability of CA 19-9 as a surveillance marker to detect recurrences on follow-up.Methods: A retrospective analysis of a prospectively maintained database of radically resected GBC who were either on observation or completed adjuvant therapy (chemotherapy or chemoradiation) were followed up 3 monthly with CA 19-9 and ultrasound (US) abdomen for the first 2 years and 6 monthly CA 19-9 and US for further 3 years. Patients with raised CA 19-9 and a recurrent lesion on US abdomen were confirmed with contrast-enhanced computed tomography (CECT) abdomen and fine-needle aspiration cytology (FNAC) of recurrent lesion to establish the diagnosis of recurrence. The performance of CA 19-9 levels (20 and more units/mL) for prediction of recurrence and its impact on survival was estimated.Results: Out of sixty patients on follow-up, 40% recurred: loco-regional (16.7%) and distant metastases (23.4%). The sensitivity, specificity, positive predictive value, and negative predictive value of CA 19-9 in detecting recurrence were 79.1%, 97.2%, 95%, and 87.5%, respectively. The median disease-free survival was 56 months versus 15 months (P = 0.008, hazard ratio [HR]: 7.4 [1.3-40]) and the median overall survival was not reached versus 20 months (P = 0.000, HR: 10.7 [confidence interval 4.2-27.3]) for CA 19-9 levels less than and more than 20 ng/mL.Conclusions: Based on the high positive and negative predictive value in our dataset, CA 19-9 can be used as a surveillance biomarker for follow-up of radically resected GBC. Raised levels of >20 ng/mL should be correlated with imaging findings and any suspicious lesion should be confirmed for recurrence by FNAC and CECT abdomen. Levels >20 ng/mL should be taken as a threshold for suspecting recurrence.

oncology
In silico analysis unveiling potential biomarkers in gallbladder carcinogenesis

Raviranjan Kumar Gupta,Ravi Bhushan,Saket Kumar,Shyam Babu Prasad

DOI: https://doi.org/10.1038/s41598-024-61762-4

IF: 4.6

2024-06-26

Scientific Reports

Abstract:Gallbladder cancer (GBC) is a rare but very aggressive most common digestive tract cancer with a high mortality rate due to delayed diagnosis at the advanced stage. Moreover, GBC progression shows asymptomatic characteristics making it impossible to detect at an early stage. In these circumstances, conventional therapy like surgery, chemotherapy, and radiotherapy becomes refractive. However, few studies reported some molecular markers like KRAS (Kirsten Rat Sarcoma) mutation, upregulation of HER2/neu, EGFR (Epidermal Growth Factor Receptor), and microRNAs in GBC. However, the absence of some specific early diagnostic and prognostic markers is the biggest hurdle for the therapy of GBC to date. The present study has been designed to identify some specific molecular markers for precise diagnosis, and prognosis, for successful treatment of the GBC. By In Silico a network-centric analysis of two microarray datasets; (GSE202479) and (GSE13222) from the Gene Expression Omnibus (GEO) database, shows 50 differentially expressed genes (DEGs) associated with GBC. Further network analysis revealed that 12 genes are highly interconnected based on the highest MCODE (Molecular Complex Detection) value, among all three genes; TRIP13 (Thyroid Receptor Interacting Protein), NEK2 (Never in Mitosis gene-A related Kinase 2), and TPX2 (Targeting Protein for Xklp2) having highest network interaction with transcription factors and miRNA suggesting critically associated with GBC. Further survival analysis data corroborate the association of these genes; TRIP13, NEK2, and TPX2 with GBC. Thus, TRIP13, NEK2, and TPX2 genes are significantly correlated with a greater risk of mortality, transforming them from mere biomarkers of the GBC for early detections and may emerge as prognostic markers for treatment.

multidisciplinary sciences
A Study of Cyclin D1, E-cadherin, EGFR, HER- 2, Ki67, and p53 Tumor Marker Expressions in Neoplastic and Non -neoplastic Gall Bladder Lesions and their Clinico-pathological Correlation

Anshoo Agarwal,Rani Bansal,Mamta Gupta

DOI: https://doi.org/10.32553/ijmsdr.v6i11.958

2022-11-26

International Journal of Medical Science and Diagnosis Research

Abstract:Background: Worldwide gall bladder cancer (GBC) is known to be the commonest malignant tumour of the biliary tract. It is the most aggressive carcinoma of the biliary tract with short median survival from the time of diagnosis. The aggressive biologic behaviour of the carcinoma and non-availability of sensitive screening tests for early detection may be responsible for the poor prognosis associated with GBC. Material and Methods: Patients diagnosed with neoplastic and non-neoplastic gallbladder lesions in the Department of Pathology, Subharti Medical College in India were included in the study. Gall bladder biopsies findings and the clinic-pathological data were compiled and different immune-markers diagnostic and therapeutic usefulness were studied . Results: 24 (24.0%) of the cases were in the age group of 51-60 Years. In 38 (38.0%) of the cases the site of lesion was Fundus. 55 (55.0%) of cases had associated stones. 36 (36.0%) of them had P53: strong over expression, 40 (40.0%) of the them had ki67: strong over expression, 25 (25.0%) had EGFR: strong over expression whereas negative expression for Her2/Neu was found in 61 (61.0%) of the cases. Cyclin D1: moderate over expression was found in 27 (27.0%) of them and moderate over expression of E-cadherin were found in 22 (23.2%) cases. Conclusions: Novel prognostic biomarkers could bring about the needed breakthrough in gall bladder cancer diagnosis and treatment. We conclude that the biomarkers studied by us may help in the identification of cases who may benefit tremendously from adjuvant and targeted therapies. Key words: Cyclin D1, E-cadherin, EGFR, HER- 2, Ki67, p53, tumour marker, neoplastic , non –neoplastic, Gall bladder lesions.
[A comparative study on the resolution of second derivative and Fourier self-deconvolution].

Dong-mei Wang,Hai-shui Wang,Guang-fu Zeng,Shi-quan Xi

2004-02-01

Abstract:Infrared spectra of 2-alkyl-7,7,8,8-tetracyanoquinodimethane (C12H25 TCNQ, C15H31 TCNQ, C18H37 TCNQ) were measured with the resolution of 1 and 4 cm(-1). In order to identify the peak number correctly in the CH2 stretching region, second derivative and Fourier self-deconvolution were applied to the infrared spectra, respectively. The overlapping bands in the CH2 stretching region could be identified when the infrared spectra, which were measured with the resolution of 4 cm(-1), were dealt with by Fourier self-deconvolution. However, the bands overlapped in the CH2 symmetric stretching region could not be observed when these infrared spectra were dealt with by second derivative. The above results reveal that Fourier self-deconvolution method is more powerful than second derivative in identifying bands that are involved in an overlapping band feature.
[Training of child and adolescent psychiatrists].

S. Yamada,H. Ichikawa,S. Ushijima

Abstract:
Circadian variation of hypocretin-1 (orexin A) in restless legs syndrome.

P. Baier,R. Göder,M. Hallschmid

DOI: https://doi.org/10.1016/j.sleep.2008.05.006

IF: 4.842

2009-02-01

Sleep Medicine

Abstract:
Inclusion of carbohydrate antigen 242 in addition to carbohydrate antigen 19.9 in serological workup of carcinoma gall bladder: a case series analysis

Mrigank Misra,Medha Mishra,Preeti Agarwal,Sameer Gupta,Akshay Anand,Wahid Ali,Malti K. Maurya,Ajay K. Singh

DOI: https://doi.org/10.18203/2320-6012.ijrms20233700

2023-11-29

International Journal of Research in Medical Sciences

Abstract:Background: Common antigenic pool is seen because of shared embryonic origins of gall bladder cancer (GBC) and pancreas. Hence, we analyzed the role of serum carbohydrate antigen 242 (CA242) which has been studied in pancreatic cancer, in GBC. The objectives were to identify whether serum CA242 provides added advantage in diagnosis of GBC when compared to controls and to determine its cut-off value. Methods: Serum CA 19-9 level was determined by chemiluminescent micro particle assay and CA242 by enzyme linked immunosorbent assay (ELISA) of age matched cases and controls. Results: Total enrolled patients were 83 including 10 (11.7%) healthy volunteers, 22 (25.9%) chronic cholecystitis cases, and 53 (62.4%) patients with histological evidence of carcinoma. Mean age of presentation of GBC was 51.64 SD10.88 years with F: M ratio of 5.6:1. Pain (90.6%, 48/53) accompanied with jaundice was significantly associated with GBC well reflected by significantly raised serum total bilirubin (p=0.011), direct bilirubin (p=0.008) along with alkaline phosphatase levels (p=0.001). Significantly higher median value of CA 19-9 and CA242 was observed in GBC when compared to CC and healthy volunteers (p 2.5 cm) and serum levels of CA242. The best cut-off limit for CA242 was 45.25 IU/ml. The specificity for carcinoma diagnosis increased to 100% when CA242 was included along with CA 19.9 in serological estimation. Conclusions: We recommend that CA antigen 19-9 may be complimented with CA242 for serological identification of malignancy in the gall bladder.
Model Based on Alkaline Phosphatase and Gamma-Glutamyltransferase for Gallbladder Cancer Prognosis

Xin-Sen Xu,Run-Chen Miao,Ling-Qiang Zhang,Rui-Tao Wang,Kai Qu,Qing Pang,Chang Liu

DOI: https://doi.org/10.7314/apjcp.2015.16.15.6255

Abstract:Purpose: To evaluate the prognostic value of alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT) in gallbladder cancer (GBC). Materials and methods: Serum ALP and GGT levels and clinicopathological parameters were retrospectively evaluated in 199 GBC patients. Receiver operating characteristic (ROC) curve analysis was performed to determine the cut-off values of ALP and GGT. Then, associations with overall survival were assessed by multivariate analysis. Based on the significant factors, a prognostic score model was established. Results: By ROC curve analysis, ALP≥210 U/L and GGT≥43 U/L were considered elevated. Overall survival for patients with elevated ALP and GGT was significantly worse than for patients within the normal range. Multivariate analysis showed that the elevated ALP, GGT and tumor stage were independent prognostic factors. Giving each positive factor a score of 1, we established a preoperative prognostic score model. Varied outcomes would be significantly distinguished by the different score groups. By further ROC curve analysis, the simple score showed great superiority compared with the widely used TNM staging, each of the ALP or GGT alone, or traditional tumor markers such as CEA, AFP, CA125 and CA199. Conclusions: Elevated ALP and GGT levels were risk predictors in GBC patients. Our prognostic model provides infomration on varied outcomes of patients from different score groups.
Can median nail dystrophy be an adverse effect of alitretinoin treatment?

A. H. Winther,A. Bygum

DOI: https://doi.org/10.2340/00015555-1853

2014-04-02

Abstract:Median canaliform nail dystrophy is an unusual condition of the nail, most often affecting the thumb (1). It is characterized by a longitudinal split or canal in the nail with small transversal fissures, in a fir-tree configuration. The condition is diagnosed based on its clinical features (2, 3). While the underlying mechanism is unknown, it has been suggested that median canaliform nail dystrophy is the result of a temporary defect in the nail matrix, following dyskeratinization or focal infection, or alternatively is due to self-inflicted trauma to the nail or nail bed. Familial cases have been reported (2, 3). Spontaneous remission is often seen, but the condition can be recurrent (1). Three case reports of median canaliform nail dys-trophy as an adverse effect of acne treatment with isotretinoin (13-cis-retinoic acid) have been published (3–5). Alitretinoin (9-cis-retinoic acid), on the other hand, is used in the treatment of severe chronic hand eczema (6–8). We report here a case of median canali-form nail dystrophy that developed in a patient treated with alitretinoin for severe hand eczema. A 53-year-old man, with a history of chronic dyshidrotic and keratotic hand and foot eczema, developed nail changes after receiving alitretinoin treatment for 16 months. The changes were most prominent on the thumbnails, where he presented median longitudinal ridging and splitting with transversal fissures. There were both horizontal and fir-tree shaped fissures among the transversal changes. Minor nail plate dystrophy was seen on the other nails, and all nails on both hands had ragged cuticles and enlarged lunulae. The patient's eczema was diagnosed in 1998 and initial treatment with topical and systemic steroids, azathioprine, metho-trexate, acitretin, cyclosporine or mycophenolate mofetil had either adverse effects or worked insufficiently. In 2008, alitreti-noin became available on the Danish market and it was prescribed to the patient in 2009. He initially received 30 mg daily, but developed adverse effects, such as headache, vertigo and universal dry skin with pruritus, after less than 1 month's treatment. A reduction in the dose was tried, first to 30 mg every third day, and later to 10 mg daily, but the adverse effects remained and the treatment was discontinued after 6 months. In 2012, the patient's eczema worsened and alitretinoin was reintroduced at a daily dose of 10 mg. After being treated with alitretinoin for 16 months, the patient developed the characteristic nail findings, which were diagnosed as median canaliform nail dystrophy (Fig. 1A). …
Cmar_a_255480 4475..4482

Zeyang Chen,Zining Liu,Yuyang Zhang,Pengyuan Wang,Hongqiao Gao

2020-01-01

Abstract:*These authors contributed equally to this work Purpose: This study aimed to evaluate the efficiency of several parameters, including the neutrophil-to-lymphocyte ratio (NLR) obtained from preoperative routine blood examination, either alone or as an adjunct to the carbohydrate antigen 19-9 (CA19-9), for the diagnosis of gallbladder carcinoma (GBC). Patients and Methods: Data from 123 patients with gallbladder cholesterol polyps (GCP), 80 with gallbladder adenoma (GA), and 103 with GBC were reviewed retrospectively. Receiver operating characteristic analysis was used to assess the sensitivity, specificity, and clinical value of the NLR, CA19-9, and their combination. Results: Values of measured indicators were significantly higher in GBC patients than in GCP or GA patients but there were no significant differences between GCP and GA patients. The combination of NLR and CA19-9 had the best diagnostic efficiency for differentiating GBC from benign lesions with 74.8% sensitivity and 89.7% specificity. However, the NLR showed no significant difference between mid-to-advanced stage and early-to-mid stage GBC. The combination of NLR and CA19-9 (53.7% sensitivity and 88.9% specificity) did not reveal any advantages over CA19-9 alone (63.0% sensitivity and 89.0% specificity) in distinguishing different stages of GBC. Conclusion: NLR and CA19-9, and their combination―parameters that are easily obtained preoperatively―have potential as diagnostic markers for GBC.
Long-term prognosis of patients with gallbladder carcinoma after curative-intent resection based on changes in the ratio of carbohydrate antigen 19-9 to total bilirubin (CA19-9/TB): a multicenter retrospective cohort study

Xue-Lei Li,Zhi-Peng Liu,Xing-Xing Su,Yi Gong,Yi-Shi Yang,Xiao-Lin Zhao,Zi-Mu Li,Jun-Jie Ding,Yi Zhu,Da-Long Yin,Chao Yu,Jin-Xue Zhou,Dong Zhang,Rui Ding,Wei Chen,Yao Cheng,Ping Yue,Zi-Ran Wang,Yan-Qi Zhang,Yan Jiang,Xian-Yu Yin,Jie Bai,Hai-Su Dai,Wan Yee Lau,Zhi-Yu Chen,

DOI: https://doi.org/10.1097/js9.0000000000001379

2024-04-17

International Journal of Surgery

Abstract:Background: The prognostic value of carbohydrate antigen 19-9 (CA19-9) is known to be affected by elevated bilirubin levels in patients with gallbladder carcinoma (GBC). The clinical significance of changes in the ratio of CA19-9 levels to total bilirubin (TB) levels in patients with GBC after curative-intent resection remains unknown. The aim of this study was to determine the prognostic value of changes in preoperative and postoperative CA19-9/TB ratio in these patients. Methods: Prospectively colleced data on consecutive patients who underwent curative-intent resection for GBC between January 2015 and December 2020 stored in a multicenter database from 10 hospitals were analysed in this retrospective cohort study. Based on the adjusted CA19-9 defined as the ratio of CA19-9 to TB, and using 2×10 3 U/μmol as the upper normal value, patients were divided into a normal group (with normal preoperative and postoperative adjusted CA19-9), a normalization group (with abnormal preoperative but normal postoperative adjusted CA19-9), and a non-normalization group (with abnormal postoperative adjusted CA19-9). The primary outcomes were overall survival (OS) and recurrence-free survival (RFS). The log-rank test was used to compare OS and RFS among the groups. The Cox regression model was used to determine factors independently associated with OS and RFS. Results: The normal group (n=179 patients) and the normalization group (n=73 patients) had better OS and RFS than the non-normalization group (n=65 patients) (the 3-year OS rates 72.0%, 58.4% and 24.2%, respectively; the RFS rates 54.5%, 25.5% and 11.8%, respectively; both P <0.001). There were no significant differences between the normal and the normalization groups in OS and RFS (OS, P =0.255; RFS, P =0.130). Cox regression analysis confirmed that the non-normalization group was independently associated with worse OS and RFS. Subgroup analysis revealed that the non-normalization group of patients who received adjuvant therapy had significantly improved OS and RFS as compared to those who did not receive adjuvant therapy (OS, P =0.025; RFS, P =0.003). Conclusions: Patients with GBC who underwent curative-intent surgical resection with postoperative abnormal levels of adjusted CA19-9 (the CA19-9/TB ratio) were associated with poorer long-term survival outcomes. Adjuvant therapy after surgery improved the long-term outcomes of these patients.

surgery
Preoperative prediction of survival in resectable gallbladder cancer by a combined utilization of CA 19–9 and carcinoembryonic antigen

Tunan Yu,Hong Yu,Xiujun Cai

DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20131734

IF: 6.133

2014-06-20

Chinese Medical Journal

Abstract:Background Currently, all frequently used staging systems in gallbladder cancer (GBC) are based on postoperative pathological examinations. In patients undergoing curative operation, there is no effective method to predict survival preoperatively. In this study, we explored whether a combined utilization of two tumor biomarkers, namely carbohydrate antigen 19–9 (CA 19–9) and carcinoembryonic antigen (CEA), could give a preoperative prediction of survival in resectable GBC. Methods Seventy-three patients who underwent radical resection for GBC were included in this study. A retrospective analysis of clinical-pathological data was conducted. Results By multivariate analysis, CA 19–9 elevation ( P <0.05) and CEA elevation ( P <0.001) were discovered as two individual factors for postoperative survival. By a combined utilization, patients were divided into three groups: patients with elevation of CEA (group I), patients with elevation of CA 19–9 but without CEA (group II), and patients with nonelevations of either CA 19–9 or CEA (group III). The cumulative 5-year survival rates in groups I, II, and III were 0, 14.0%, and 42.8%, respectively ( P <0.05). Conclusions By a combined utilization of CA 19–9 and CEA, individualized prediction of survival is available in resectable GBC before operation. Extended radical operation brings the most prognostic benefits in patients with nonelevations of either CA 19–9 or CEA. However, if operation would be in a larger-scale destructive manner, careful consideration of surgical decisions should be made in patients with elevation of tumor biomarkers, especially CEA.

medicine, general & internal
Pattern of Care and Outcomes of Gallbladder Cancer Patients: Retrospective Study from a High Incidence Region in India

Lakhan Kashyap,Arpita Singh,Subham Tomar,Anuj Gupta,Bipinesh Sansar,Amit Kumar Chaudhary,Bal Krishna Mishra,Kuraparthy Sambasivaiah,Akhil Kapoor

DOI: https://doi.org/10.1055/s-0043-1761440

2023-08-11

Abstract:Lakhan KasyapIntroduction Gallbladder cancer (GBC) is the 20th most common cancer in India with a crude incidence rate of 2.3 per 100,000 persons. Of note, it is relatively common in states which fall in the Gangetic plains. Patients often present in the advanced stage and have an unfavorable prognosis. Materials and Methods From January to June 2021, 170 treatment-naive GBC (adenocarcinoma) patients who were registered at a tertiary care cancer center in North India, were included. Data were extracted from electronic medical records and was analyzed with SPSS. Results Median age was 56 years (range 32-77 years) and 65.5% ( n = 112) were female. Incidental GBC was found in 20% patient ( n = 34). Majority of patients (79.4%, n = 135) had preserved performance status. Advanced GBC was present in 85.8% ( n = 146) patients (locally advanced = 37.0% and metastatic = 48.8%). Biliary drainage procedure was performed in 24% of patients (68% of patients with obstructive jaundice). More than half of patients (53.5%) were lost to follow-up without any treatment. There were 33 patients (19.4%) who underwent surgery and 20 of them received neoadjuvant chemotherapy. Adjuvant chemotherapy and adjuvant radiotherapy were received by 13 and 2 patients, respectively. Palliative chemotherapy was administered to 46 patients. The most common chemotherapy regimen was gemcitabine-cisplatin. At a median follow-up of 1.7 months (95% confidence interval, 1-2.4 months), 42 patients (24%) progressed and 24 patients (14%) died, with 6 months estimated progression-free survival and overall survival being 60.2 and 79%, respectively. Conclusion GBC is an aggressive and lethal malignancy predominantly affecting females in the fifth decade with dismal outcomes. Improved access to health care, an aggressive approach in operable cases, and optimization of systemic and adjuvant therapy are the need of the hour.
Impact of ABCB1 and ABCG2 Transporter in Outcome of Gallbladder Cancer

Nimisha,Sundeep S Saluja,Abhay K Sharma,Phani K Nekarakanti,Apurva,Arun Kumar,Ejaj Ahmad,Syed A Husain

DOI: https://doi.org/10.1016/j.jceh.2024.101410

Abstract:Background: Gallbladder cancer (GBC) is a biologically aggressive malignancy requiring appropriate biomarkers to improve its outcome. Role of ABC transporters (ABCB1 and ABCG2) has been linked to cancer aggressiveness, tumorigenesis and multidrug resistance. Herein, we studied the prognostic implication of ABCB1 and ABCG2 in GBC. Methods: Fresh tissue (tumour & normal) samples collected from 54 patients who underwent R0 resection, were analysed for mRNA and protein expression of ABCB1 and ABCG2 by quantitative Real-Time PCR and western blotting, respectively, in this prospective study. The molecular findings were correlated with clinical-pathological parameters using χ2 and fisher exact test. The molecular changes in ABCB1 and ABCG2 were analysed for predicting overall survival (OS), disease-free survival (DFS) and response to chemotherapy using Kaplan-Meier log-rank test and Cox regression multivariate analysis. Results: The mean age of the cohort was 50 ± 13.2 with 26 (48.1%) in patients having early stage gallbladder cancer (GBC). Over-expression of ABCB1 and ABCG2 was noted in 32/54 (59%) and 40/54 (74%) cases, respectively. The protein expression of ABCB1(P-glycoprotein) and ABCG2 (BCRP) was higher in 27/54 (50%) and 37/54 (59%) cases, respectively. The mean OS and DFS was 20.7 ± 11.5 and 19.3 ± 12.2 months at median follow-up of 24 months. The TNM stage, lymph node metastasis, and presence of gallstone were significant factors for predicting OS and DFS on multivariate analysis. Both ABCB1 and ABCG2 did not show any significant correlation with OS and DFS with similar incidences of late death and recurrence among over-expression and down-expression. Sub-group comparison suggests that change in expression pattern of ABCB1 and ABCG2 may not affect response to chemotherapy in GBC. Conclusion: Altered expression of ABCB1 and ABCG2 may not be a useful prognostic marker for survival or response to chemotherapy in GBC. Presently, histo-pathological characteristics and associated gallstones are the important predictors for survival and recurrence in GBC.
Demographic and clinicopathological Profile of Gall Bladder Cancer Patients: Study from a tertiary care center of the Sub-Himalayan region in Indo-Gangetic Belt

Amit Gupta,Sweety Gupta,Rohik Anjum T Siddeek,Jaine John Chennatt,Tanuj Singla,Deepak Rajput,Navin Kumar,Amit Sehrawat,Sanjeev Kishore,Manoj Gupta

DOI: https://doi.org/10.4103/jcar.JCar_3_21

2021-06-09

Abstract:Introduction: Gall bladder cancer (GBC) accounts for 80%-95% of biliary tract malignancies in the world. There is however striking variability in the global incidence of gallbladder cancer, reaching epidemic levels for some regions and ethnicities. The aim of this study was to evaluate the demographic and clinicopathological profile of the gallbladder cancer patients. Materials and methods: All patients of carcinoma gall bladder presenting to department of surgery in hepatopancreaticobiliary unit from July 2017 to November 2020 were included in this study. A proforma containing all the relevant details including history, examination, blood, radiology, and pathological investigations was filled. Results: A total of 326 patients of GBC were analyzed. The majority (75%) were found to be females with a mean age of 55 years. Pain abdomen was the most common presenting symptom in 81% of patients. The most common stage of presentation was stage IV and only 6 were in stage I. Two hundred and thirty three (71.4%) patients had metastatic disease at presentation. Liver infiltration at the time of diagnosis was present in 89% of patients. The most common site of metastasis was found in the liver (23.3%). GBC was more common in patients with A blood group. Baseline serum albumin levels were found to be significantly associated with the staging of GBC. Conclusions: Due to the non specific symptoms patients of GBC present at very advanced stages, high index of suspicion and health education seems to play an important role in early detection and improvement of survival.
Aggressive Surgical Approach for Gallbladder Cancer: a Single-Center Experience from Northern India

Santosh Kumar Singh,Rajnish Talwar,Narayanan Kannan,Arvind Kumar Tyagi,Pradeep Jaiswal,Adarsh Kumar

DOI: https://doi.org/10.1007/s12029-015-9766-4

Abstract:Background: Gallbladder cancer (GBC) is an aggressive disease with dismal results of surgical treatment mainly because of advanced stage at presentation. The objective of this study was to investigate whether aggressive surgical treatment can be associated with reasonable survival for patients with GBC at acceptable morbidity and mortality. Methods: A total of 113 patients with proven or presumptive diagnosis of GBC were recruited prospectively over a period of 2 years and evaluated for diagnosis and staging by appropriate investigations. Seven out of 113 patients were found to have benign pathology either intraoperatively or on histopathological examination hence excluded from follow-up and survival analysis. Out of 32 potentially resectable patients, only 21 patients could finally be resected with curative intent. Patients found unresectable/metastatic disease intraoperatively (n = 11) were treated with palliative chemotherapy if eligible for the same. Short-term morbidity, perioperative mortality, disease-free survival (DFS), and median overall survival (OS) of surgically resected patients were analyzed. Median OS of resected patients was compared with that of unresectable patients. Results: Overall resectability rate in this study cohort was 19.8 % (21/106). Overall mortality was 4.7 % and morbidity was 42.8 %. Stage distribution of resected patients was as follows: stage II (3), stage IIIA (9), stage IIIB (8), and stage IVA (1). DFS at 12 and 18 months was found to be 82.5 and 73.3 %, respectively. Mean DFS was 19.9 months (SE 1.42, 95 % CI). Mean OS for resected patients was 21 months and that for unresectable patients was 11.3 months only. Both groups were compared using log rank (Mantel-cox) test and statistically significant difference in OS was observed (p value <0.0001). Conclusion: Since curative resection is the only chance of cure, aggressive surgical approach adopted by us is justified with acceptable mortality and morbidity and encouraging overall survival.

[How evidence-based are print- and online mass media in Austria? A quantitative analysis].

Utility of triple tumor markers CA19-9, CA125 and CEA in predicting advanced stage of carcinoma gallbladder: a retrospective study

[Analysis of Treatment Modalities and Prognosis of Patients with Gallbladder Cancer in China from 2010 to 2017].

Nanopatterned PMMA-Yb:Er/Tm:Lu2O3 composites with visible upconversion emissions

Serum Levels of Interleukin-6 and Tumor Necrosis Factor-Alpha in Diagnosis and Prognosis of Gallbladder Cancer: A Pilot Study

Raised carbohydrate antigen 19-9 levels detect recurrences and impacts overall and disease-free survival in radically resected gallbladder cancer: A simple surveillance marker?

In silico analysis unveiling potential biomarkers in gallbladder carcinogenesis

A Study of Cyclin D1, E-cadherin, EGFR, HER- 2, Ki67, and p53 Tumor Marker Expressions in Neoplastic and Non -neoplastic Gall Bladder Lesions and their Clinico-pathological Correlation

[A comparative study on the resolution of second derivative and Fourier self-deconvolution].

[Training of child and adolescent psychiatrists].

Circadian variation of hypocretin-1 (orexin A) in restless legs syndrome.

Inclusion of carbohydrate antigen 242 in addition to carbohydrate antigen 19.9 in serological workup of carcinoma gall bladder: a case series analysis

Model Based on Alkaline Phosphatase and Gamma-Glutamyltransferase for Gallbladder Cancer Prognosis

Can median nail dystrophy be an adverse effect of alitretinoin treatment?

Cmar_a_255480 4475..4482

Long-term prognosis of patients with gallbladder carcinoma after curative-intent resection based on changes in the ratio of carbohydrate antigen 19-9 to total bilirubin (CA19-9/TB): a multicenter retrospective cohort study

Preoperative prediction of survival in resectable gallbladder cancer by a combined utilization of CA 19–9 and carcinoembryonic antigen

Pattern of Care and Outcomes of Gallbladder Cancer Patients: Retrospective Study from a High Incidence Region in India

Impact of ABCB1 and ABCG2 Transporter in Outcome of Gallbladder Cancer

Demographic and clinicopathological Profile of Gall Bladder Cancer Patients: Study from a tertiary care center of the Sub-Himalayan region in Indo-Gangetic Belt

Aggressive Surgical Approach for Gallbladder Cancer: a Single-Center Experience from Northern India